# Pizarra — PT-pseudo_4d54f04e26ae (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_4d54f04e26ae
Task: 1

Encounter: Urology - outpatient on 17 Feb 2025.
Referrer: Dr. R. Visser (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 66-year-old male
  - PSA: 34.7 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.352 ng/mL²
  - PSA velocity: 0.68 ng/mL/yr
  - Prior PSA: 29.7 ng/mL
  - Prostate volume: 99.5 mL
  - Months since last PSA: 1
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.739 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Osteoarthritis
  - Problem list / PMHx: Osteoarthritis
  - Current medication: paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 34.7 ng/mL. PI-RADS 4. PSAD 0.35. Prostate volume 100 mL. DRE nodus. csPCa 0.74.

Vitals: weight 69 kg, height 174 cm, BMI 22.8, BP 108/83 mmHg, HR 67 bpm. Smoking: Ex-smoker (13 pack-yr, quit 2007).

Chief complaint: Sustained PSA elevation alongside a Negative prior biopsy defines the current clinical presentation.

History: A sixty-six-year-old ICT consultant, never married but residing with his partner, first entered clinical evaluation in early 2023 due to an incidental PSA spike. Chronic mild lower urinary tract complaints persist, currently registering a 4 on the IPSS scale, while osteoarthritis is managed solely with paracetamol on an as-needed basis. Tobacco use ceased in 2007 following a cumulative 13 pack-year exposure; leisure activities now feature weekend hiking alongside his partner, accompanied by moderate alcohol intake averaging three units per week. Recent outpatient assessments covered routine thyroid function screening and an ophthalmology consultation for early cataract development, both demonstrating stability. Geographic distance places his residence over ninety minutes from the medical center, prompting a specific preference for remote telephone consultations during subsequent care phases.

Physical examination: DRE — prostate texture: asymmetrically hypertrophied with a distinct, firm nodule localized to the right mid-gland. General assessment remains within normal limits, displaying unremarkable cardiopulmonary findings and stable resting vital parameters.

Patient info: ICT consultant; Never married; Lives with partner.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 3 units / week; exercise Hiking on weekends; IPSS score: 4/35 (mild LUTS).

Recent other appointments: Endocrine — thyroid screening; Ophthalmology — cataract review.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.56 +/- 0.21   (95% CI 0.14-0.92)

Where the uncertainty comes from:
  - aleatoric  dA = 0.19  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.10  (few labelled cases resemble this one)
  - 4.0 effective neighbours out of 10; 3 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no, yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=1.0, psa=34.7, age=66.0, psad=0.352, dre_ord=1.0, vol=99.5, n_pmhx=1.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the patient's PSA velocity (0.68 ng/mL/yr) and the PSA trend (Prior PSA 29.7 ng/mL), which indicate a rapid rise, against the PI-RADS 4 score and the prior negative biopsy status. It also missed the context provided by the full laboratory panel and the mpMRI report, which are crucial for assessing the extent of the lesion suggested by the PI-RADS 4.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests a 'discuss' tier decision (0.56 +/- 0.21). A failure mode is the contradiction between the high csPCa predicted probability (0.739) and the prior negative biopsy. Another failure mode is the wide aleatoric error bar (dA = 0.19), suggesting the underlying data distribution is highly heterogeneous, meaning the simple classification is inherently unstable for this patient profile. A third failure mode is ignoring the clinical significance of the PSA velocity (0.68 ng/mL/yr) in the context of a high PSA level (34.7 ng/mL).

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details significant peripheral extension or high-risk features, it would strongly push towards biopsy.
  <document> PSA history (trend) -> If the trend shows a steeper rise or a more concerning trajectory, it would increase the urgency for intervention.
  <document> laboratory results -> If the lab panel shows any markers (e.g., inflammation, other cancers) that modify the risk profile, it would alter the decision threshold.
  <document> previous GP / urology consultation notes -> These notes might contain context regarding the LUTS or any prior discussions about the PSA trajectory.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line.

  **radiology / mpMRI report**
  Radiology Division, UMCG Groningen — 10 February 2025 | Modality: Prostate mpMRI
  FINDINGS:
  Glandular architecture measures 99.5 mL overall, exhibiting asymmetric hypertrophy. T2-weighted sequences highlight a sharply demarcated hypointense area in the right mid-gland peripheral zone, spanning roughly 14 x 11 x 10 mm. DWI shows pronounced diffusion restriction with correspondingly depressed ADC metrics. DCE sequences capture early, focal contrast uptake within that identical zone. Seminal vesicles maintain bilateral integrity. Capsular margins remain intact without extracapsular spread, vesicular invasion, or suspicious nodal enlargement. Bladder neck and urethral canal appear normal.
  IMPRESSION:
  PI-RADS 4 lesion in the right mid-gland peripheral zone. PSAD 0.352 ng/mL/mL. csPCa predicted probability 0.739.

  **PSA history**
  {"case_id": "PT-pseudo_4d54f04e26ae", "psa_trend": [{"date": "Feb 2023", "val": 5.0}, {"date": "Aug 2023", "val": 11.4}, {"date": "Feb 2024", "val": 13.5}, {"date": "Aug 2024", "val": 12.7}, {"date": "Feb 2025", "val": 34.7}]}

  **laboratory results**
  {"name": "PSA", "val": "34.7 ng/mL", "date": "22 Jan 2025", "flag": "H"}, {"name": "Free PSA", "val": "8.11 ng/mL", "date": "22 Jan 2025", "flag": ""}, {"name": "%Free PSA", "val": "23%", "date": "22 Jan 2025", "flag": ""}, {"name": "Haemoglobin", "val": "14.4 g/dL", "date": "22 Jan 2025", "flag": ""}, {"name": "WBC", "val": "7.6 x10^9/L", "date": "22 Jan 2025", "flag": ""}, {"name": "Platelets", "val": "232 x10^9/L", "date": "22 Jan 2025", "flag": ""}, {"name": "Creatinine", "val": "92 umol/L", "date": "22 Jan 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "22 Jan 2025", "flag": ""}, {"name": "Testosterone", "val": "11.5 nmol/L", "date": "22 Jan 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "109 U/L", "date": "22 Jan 2025", "flag": ""}, {"name": "LDH", "val": "149 U/L", "date": "22 Jan 2025", "flag": ""}}

  **previous GP / urology consultation notes**
  {"date": "23 Feb 2024", "author": "Dr. R. Visser (GP)", "text": "Serum PSA levels have held steady at 29.5 ng/mL subsequent to the Negative systematic sampling conducted earlier this year. The sustained elevation prompted a referral to the urology outpatient department for comprehensive evaluation. General health remains stable, with osteoarthritis symptoms adequately controlled via paracetamol as required."}, {"date": "20 Oct 2024", "author": "Dr. R. Visser (GP)", "text": "Recent laboratory panels indicate a marginal PSA rise to 29.7 ng/mL. Subjective complaints include minor lower urinary tract complaints without accompanying hematuria or skeletal discomfort. A subsequent clinical encounter has been arranged for the urology group to evaluate the forthcoming MRI findings, given the continued upward trajectory despite the initial Negative diagnostic phase."}

NOT RETRIEVED
  get_family_history - Not called as per retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  PI-RADS 4 lesion in the right mid-gland peripheral zone
  PSA velocity of 0.68 ng/mL/yr
  csPCa predicted probability of 0.739
  PSA level of 34.7 ng/mL

  AGAINST sampling this patient now:
  Prior biopsy was Negative
  Capsular margins remain intact without extracapsular spread, vesicular invasion, or suspicious nodal enlargement

WHERE THIS LEANS
  The evidence strongly argues for sampling due to the high-risk imaging finding (PI-RADS 4) and the concerning PSA velocity, which contradicts the prior negative biopsy. This leans towards a strong recommendation for biopsy.

[Sections actually revealed in this consultation: psa_trend, radiology_report, laboratory_results, previous_notes. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

No frozen image embeddings are on file for this patient, so the image-embedding head could not be run. This contributes NO evidence in either direction — do not read the absence of a score as reassurance.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the evidence strongly supports intervention due to a PI-RADS 4 lesion and a concerning PSA velocity of 0.68 ng/mL/yr, which contradicts the prior negative biopsy. The decision is driven by the high-risk imaging finding (PI-RADS 4) and the rising PSA trend from 29.7 ng/mL to 34.7 ng/mL, despite the prior negative result.

Variables that carried weight: bx=decisive, age=noted, psa=decisive, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: psa_trend, radiology_report, laboratory_results, previous_notes
